Bridgebio Pharma, Inc. (BBIO) — SEC Filings
Bridgebio Pharma, Inc. (BBIO) — 39 SEC filings. Latest: 8-K (May 8, 2026). Includes 20 8-K, 6 SC 13G/A, 5 10-Q.
View Bridgebio Pharma, Inc. on SEC EDGAR
Overview
Bridgebio Pharma, Inc. (BBIO) is a publicly traded company tracked on ReadTheFiling. The most recent enriched filing is a 4 filed on Apr 13, 2026: On April 13, 2026, BridgeBio Pharma, Inc. filed a Form 4, reporting changes in beneficial ownership of securities. The filing pertains to the period of report ending April 9, 2026. Neil Kumar is listed as a reporting person.
Sentiment Summary
Across 39 filings, the sentiment breakdown is: 1 bearish, 36 neutral, 2 mixed. The dominant filing sentiment for Bridgebio Pharma, Inc. is neutral.
Filing Type Overview
Bridgebio Pharma, Inc. (BBIO) has filed 1 4, 20 8-K, 5 10-Q, 1 DEFA14A, 2 DEF 14A, 6 SC 13G/A, 3 SC 13D/A, 1 10-K with the SEC between Jan 2024 to May 2026.
Filings by Year
Recent SEC Filings (39)
Risk Profile
Risk Assessment: Of BBIO's 30 recent filings, 1 were flagged as high-risk, 14 as medium-risk, and 15 as low-risk. The overall risk profile suggests relatively low risk with generally favorable filings.
Financial Highlights
| Metric | Value |
|---|---|
| Revenue | $10.5M |
| Net Income | -$143.5M |
| EPS | N/A |
| Debt-to-Equity | N/A |
| Cash Position | N/A |
| Operating Margin | N/A |
| Total Assets | N/A |
| Total Debt | N/A |
Key Executives
- Neil Kumar
- 0001742485
- Matthew Bloom
- George R. Roberts
- Henry R. Kravis
- DAVID C. OTT
- O. ANDREAS HALVORSEN
- ROSE S. SHABET
- Dr. Philip P. Brooks
- Dr. Jonathan M. Fleming
- Dr. Brian Stephenson
- Eric Aguiar, M.D.
- Jennifer E. Cook
- Andrea J. Ellis
- Fred Hassan
Industry Context
BridgeBio Pharma operates in the highly competitive biotechnology sector, focusing on developing therapies for genetic diseases. The industry is characterized by long development cycles, high R&D costs, and significant regulatory hurdles. Success often depends on innovation, strategic partnerships, and the ability to secure substantial funding for clinical trials and commercialization.
Top Tags
8-k (6) · sec-filing (6) · financials (5) · material-agreement (4) · 10-Q (4) · ownership-change (3) · filing (3) · financial-reporting (3) · governance (3) · pharmaceuticals (3)
Key Numbers
| Metric | Value | Context |
|---|---|---|
| Net Loss | $143.5M | for the three months ended June 30, 2025, increased from $105.2M in 2024 |
| Total Revenue | $10.5M | for the three months ended June 30, 2025, up from $8.2M in 2024 |
| Research and Development Expenses | $110.3M | for the three months ended June 30, 2025, increased from $85.1M in 2024 |
| General and Administrative Expenses | $45.1M | for the three months ended June 30, 2025, increased from $38.7M in 2024 |
| Convertible Senior Notes Interest Rate | 1.75% | for notes due in 2031 |
| Reporting Period End Date | 2024-09-30 | Indicates the end of the fiscal quarter for which financial data is reported. |
| Financing Agreement Date | 2024-01-17 | Specific date related to a financing agreement mentioned in the filing. |
| QED Therapeutics Inc. Start Date | 2019-10-01 | Indicates the start of a period related to QED Therapeutics Inc. |
| Period End Date | 20240630 | The filing covers financial and operational data up to this date. |
| Filing Date | 20240801 | The date the 10-Q was officially submitted to the SEC. |
| Q1 2024 Start Date | 2024-01-01 | Reporting period for Q1 2024 |
| Directors to be elected | 5 | To serve as Class II directors until the annual meeting following the year ending December 31, 2026. |
| Additional shares for stock plan | 6,500,000 | Increase in the number of shares of common stock reserved for issuance under the 2021 Stock Option and Incentive Plan. |
| Fiscal Year End | 2024 | For which Deloitte & Touche LLP is proposed to be ratified as the independent auditor. |
| Director Term End Year | 2026 | Annual meeting following the year ending December 31, 2026, for elected directors. |
Frequently Asked Questions
What are the latest SEC filings for Bridgebio Pharma, Inc. (BBIO)?
Bridgebio Pharma, Inc. has 39 recent SEC filings from Jan 2024 to May 2026, including 20 8-K, 6 SC 13G/A, 5 10-Q. Each filing includes an AI-generated plain-English summary.
What is the overall sentiment of BBIO filings?
Across 39 filings, the sentiment breakdown is: 1 bearish, 36 neutral, 2 mixed. The dominant sentiment is neutral.
Where can I find Bridgebio Pharma, Inc. SEC filings explained simply?
ReadTheFiling provides AI-powered plain-English summaries of all Bridgebio Pharma, Inc. (BBIO) SEC filings, including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, and insider trades.
What are the key financial highlights for Bridgebio Pharma, Inc.?
Key financial highlights from Bridgebio Pharma, Inc.'s most recent 10-Q include metrics such as revenue, net income, EPS, and debt ratios. Visit the filing detail page for the full breakdown.
What is the investment thesis for BBIO?
The investment thesis for BBIO includes bull, base, and bear case scenarios derived from AI analysis of recent SEC filings.
Who are the key executives at Bridgebio Pharma, Inc.?
Key executives identified across Bridgebio Pharma, Inc.'s filings include Neil Kumar, 0001742485, Matthew Bloom, George R. Roberts, Henry R. Kravis and 11 others.
What are the main risk factors for Bridgebio Pharma, Inc. stock?
Of BBIO's 30 assessed filings, 1 were flagged high-risk, 14 medium-risk, and 15 low-risk.
What are recent predictions and forward guidance from Bridgebio Pharma, Inc.?
Forward guidance and predictions for Bridgebio Pharma, Inc. are extracted from SEC filings as they are enriched.